Spotlight

The following is a summary of “Impressions and Perceptions of a Smartphone and Smartwatch...

The following is a summary of “Respiratory Oscillometry and Functional Performance in Different...

Several clinical trials have tested the efficacy and safety of valbenazine and deutetrabenazine in patients with TD.

The following is a summary of “High Blood Eosinophil Count at Stable State is Not Associated with...

The following is a summary of “Automated Quantification of QT-Intervals by an Algorithm: A...

Emerging evidence underscores the significant impact of diet on IBD development and treatment.

Deep brain stimulation offers advantages such as adjustability, reversibility, and the potential for rapid and long-term improvement in tardive dyskinesia.

Targeted microbiota manipulation using probiotics, prebiotics, synbiotics, and fecal microbiota transplantation holds potential for IBD treatment.

Annual training and reliable new tools can help physicians improve tardive dyskinesia screening and symptom measurement.

Patients with inflammatory bowel diseases often experience insomnia and various mental health conditions that healthcare providers should monitor.

Advances in the management of IBD may support a shift from hospital-based care to community-based care.

There are approximately 600,000 people in the US who are living with TD—65% of them have not been diagnosed.

Study results indicate that switching from intravenous to subcutaneous vedolizumab in patients with IBD appears to be safe and effective.

The Tardive Dyskinesia Impact Scale complements the Abnormal Involuntary Movement Scale by combining clinician-rated and patient-reported perspectives.

The Extrapyramidal Symptom Rating Scale and an abbreviated version of the scale were both validated for measuring the impact of tardive dyskinesia.